Craft

H-CYTE

Stock Price

$0.5

2023-09-08

Market Capitalization

$625 K

2023-09-08

Revenue

$453.5 K

FY, 2022

H-CYTE Summary

Company Summary

Overview
H-CYTE (formerly known as Medovex) builds and develops medical technology products and services. It offers DenerveX system that provides relief from pain associated with facet joint syndrome. For biomedical services, the company manages Lung Health Institute. Lung Health Institute focuses on regenerative medicine that specializes in cellular therapies to treat chronic obstructive pulmonary disease (COPD) and other chronic lung diseases.
Type
Public
Status
Active
Founded
2013
HQ
Tampa, FL, US | view all locations
Website
https://www.hcyte.com/
Cybersecurity rating
Sectors

Key People

  • Jeremy Daniel

    Jeremy Daniel, Chief Financial Officer

  • William E. Horne

LocationsView all

1 location detected

  • Tampa, FL HQ

    United States

    201 E Kennedy Blvd #700

H-CYTE Financials

Summary Financials

Net income (Q3, 2023)
($495.8K)
Cash (Q3, 2023)
$544.0K
EBIT (Q3, 2023)
($421.3K)
Enterprise value
$191.5K

Footer menu